News Releases

Lyell Immunopharma To Participate in the Baird 2026 Global Healthcare Conference

September 14, 2026

Read More

Lyell Immunopharma Completes Manufacturing Transfer for LYL273 and Provides Updated Timeline on Phase 1/2 Trial in Metastatic Colorectal Cancer

September 10, 2026

Read More

Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2026

August 6, 2026

Read More

Lyell Immunopharma Announces Participation in H.C. Wainwright 4th Annual Cell Therapy Virtual Conference

June 25, 2026

Read More

Lyell Immunopharma Presents Updated Safety Data and Translational Insights for Rondecabtagene Autoleucel (Ronde-Cel) in Patients with Large B-Cell Lymphoma at European Hematology Association 2026 Congress

June 12, 2026

Read More

Lyell Immunopharma Provides Update on Safety Profile of LYL273 in Relapsed or Refractory Metastatic Colorectal Cancer and Amends Phase 1 Trial to Phase 1/2 Expansion 

June 8, 2026

Read More

Lyell Immunopharma to Present Phase 1/2 Safety and Translational Data for Ronde-Cel in Large B-Cell Lymphoma at the European Hematology Association 2026 Congress

June 4, 2026

Read More

Lyell Immunopharma Announces Participation in Goldman Sachs 47th Annual Global Healthcare Conference 2026

June 1, 2026

Read More

Lyell Immunopharma Announces Participation in May Investor Conferences

May 12, 2026

Read More

Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2026

May 6, 2026

Read More